Molecular and Immune Correlates of Lymphocyte Activation Gene-3 Expression in Renal Cell Carcinoma.

Harshitha Dudipala¹, Adam J Dugan², Unnati Jariwala², Karyn Ronski², Jacob Mercer², Eddy Saad³, Jad El Masri³, Marc Machaalani³, Mustafa Saleh³, Kayla Viets Layng², Yingying Yu², Sabina Signoretti³, David Braun⁴, Sumanta Pal⁵, Toni K Choueiri³, Rana R McKay¹

¹Moores Cancer Center, University of California San Diego, La Jolla, CA.

²Tempus AI, Inc., Chicago, IL.

³Dana Farber Cancer Institute, Boston, MA.

⁴Yale Cancer Center, New Haven, CT.

⁵City of Hope Comprehensive Cancer Center, Duarte, CA.

PubMed DOI

Abstract

BACKGROUND: Lymphocyte Activation Gene-3 (LAG-3) is an immune checkpoint receptor that has emerged as a biomarker of interest but its relationship with outcomes in renal cell carcinoma (RCC) is poorly characterized. This study evaluates molecular and immune correlates of LAG-3 expression and its association with outcomes. METHODS: De-identified DNA-NGS data (xT) and RNA-NGS (xR) from patients (pt…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.